Pharmaceutical Products M&A Transactions

Fulcrum Therapeutics

Fulcrum Therapeutics and Slate Medicines merge, creating a new Nasdaq-listed biotech focused on migraine treatments, bolstered by $245 million in new funding.

LEO Pharma secures global rights to dersimelagon, a promising oral therapy for rare skin conditions EPP and XLP, in a deal valued up to $435 million.

Jasper Therapeutics

Jasper Therapeutics merges with Kira Pharmaceuticals, enhancing its immunology pipeline with three key assets and securing $132 million in financing for extended operational runway.

PTC Therapeutics secures ST-920 Fabry gene therapy from Sangamo Therapeutics for up to $211M, enhancing its rare disease treatment portfolio.

Wise Equity, via Wisequity VI, takes majority control of E-Pharma Trento, a specialized CDMO, from Unifarm. Strategic growth planned for nutraceuticals.

PromoPharma acquires New Penta, a specialized nutrition brand, from White Bridge Investments II. Aurora Growth Capital backs the strategic expansion.